We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact
Read MoreHide Full Article
Thermo Fisher Scientific, Inc. (TMO - Free Report) recently entered into an exclusive distribution agreement with Aesku. Group (“Aesku”) to market, sell and support their portfolio of FDA-cleared IFA products, automated instruments and software in the United States. With this partnership, Thermo Fisher positions itself to provide laboratories in the United States with a full array of automated diagnostic tools and procedures.
The recent development will fortify Thermo Fisher’s Immunology solutions.
More on Collaboration
According to the terms of the deal, Thermo Fisher will exclusively sell and market Aesku goods in the United States. Customers in the United States will also receive installation, maintenance and support services from Thermo Fisher. All items covered by the agreement will continue to be manufactured by Aesku.
Thermo Fisher will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics, ImmunoCAP allergy diagnostics and Phadia Laboratory Systems with complementary reagents and systems from Aesku. This will lead to faster and more accurate diagnoses for patients.
Strategic Implications
The collaboration with Aesku demonstrates Thermo Fisher's commitment to empowering customers to make the world a healthier place by providing new solutions that aid in the identification and diagnosis of complicated autoimmune illnesses. Aesku has pioneered unique and efficient solutions that effortlessly integrate into the company's existing portfolio.
Image Source: Zacks Investment Research
Aesku's commitment to innovation in autoimmune diagnostics aligns seamlessly with Thermo Fisher's mission of enabling customers to make the world healthier, cleaner and safer. Both companies are setting new benchmarks for accuracy and efficiency in autoimmunity testing, ensuring clinicians and patients receive the most advanced diagnostic capabilities available.
Industry Prospects
Per a report by Markets and Markets, the global immunoassay market was estimated to be worth $35 billion in 2023 and is poised to reach $46.7 billion by 2028 at a CAGR of 5.9%. Market growth is driven by the rising incidence of chronic and infectious diseases and growth in biotechnology and biopharmaceutical industries.
Other Notable Developments
In December 2023, Thermo Fisher entered into a collaboration with Project HOPE, a leading global health and humanitarian organization working on the front lines of the world’s health challenges. The partnership will focus on improving the well-being and treatment outcomes of adolescents and young persons living with HIV in Nigeria, the country with the second-largest HIV epidemic worldwide.
Earlier this year, Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers became the first and only immunoassays to receive breakthrough designation and FDA clearance for the risk assessment and clinical management of preeclampsia. This potentially life-threatening condition disproportionately impacts pregnant black women.
Price Performance
In the past six months, TMO’s shares have dropped 2.3% against the industry’s rise of 4.2%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Thermo Fisher (TMO) to Allocate IFA Testing Kits With New Pact
Thermo Fisher Scientific, Inc. (TMO - Free Report) recently entered into an exclusive distribution agreement with Aesku. Group (“Aesku”) to market, sell and support their portfolio of FDA-cleared IFA products, automated instruments and software in the United States. With this partnership, Thermo Fisher positions itself to provide laboratories in the United States with a full array of automated diagnostic tools and procedures.
The recent development will fortify Thermo Fisher’s Immunology solutions.
More on Collaboration
According to the terms of the deal, Thermo Fisher will exclusively sell and market Aesku goods in the United States. Customers in the United States will also receive installation, maintenance and support services from Thermo Fisher. All items covered by the agreement will continue to be manufactured by Aesku.
Thermo Fisher will continue to meet the evolving needs of laboratories and healthcare professionals by expanding its immunology product portfolio of EliA autoimmune diagnostics, ImmunoCAP allergy diagnostics and Phadia Laboratory Systems with complementary reagents and systems from Aesku. This will lead to faster and more accurate diagnoses for patients.
Strategic Implications
The collaboration with Aesku demonstrates Thermo Fisher's commitment to empowering customers to make the world a healthier place by providing new solutions that aid in the identification and diagnosis of complicated autoimmune illnesses. Aesku has pioneered unique and efficient solutions that effortlessly integrate into the company's existing portfolio.
Aesku's commitment to innovation in autoimmune diagnostics aligns seamlessly with Thermo Fisher's mission of enabling customers to make the world healthier, cleaner and safer. Both companies are setting new benchmarks for accuracy and efficiency in autoimmunity testing, ensuring clinicians and patients receive the most advanced diagnostic capabilities available.
Industry Prospects
Per a report by Markets and Markets, the global immunoassay market was estimated to be worth $35 billion in 2023 and is poised to reach $46.7 billion by 2028 at a CAGR of 5.9%. Market growth is driven by the rising incidence of chronic and infectious diseases and growth in biotechnology and biopharmaceutical industries.
Other Notable Developments
In December 2023, Thermo Fisher entered into a collaboration with Project HOPE, a leading global health and humanitarian organization working on the front lines of the world’s health challenges. The partnership will focus on improving the well-being and treatment outcomes of adolescents and young persons living with HIV in Nigeria, the country with the second-largest HIV epidemic worldwide.
Earlier this year, Thermo Scientific B·R·A·H·M·S PlGF plus KRYPTOR and B·R·A·H·M·S sFlt-1 KRYPTOR novel biomarkers became the first and only immunoassays to receive breakthrough designation and FDA clearance for the risk assessment and clinical management of preeclampsia. This potentially life-threatening condition disproportionately impacts pregnant black women.
Price Performance
In the past six months, TMO’s shares have dropped 2.3% against the industry’s rise of 4.2%.
Zacks Rank and Key Picks
Thermo Fisher currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the broader medical space are Haemonetics (HAE - Free Report) , Insulet (PODD - Free Report) and DexCom (DXCM - Free Report) . While Haemonetics and DexCom each carry a Zacks Rank #2 (Buy), Insulet presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Haemonetics’ stock has risen 11.6% in the past year. Earnings estimates for Haemonetics have increased from $3.82 to $3.86 in 2023 and $4.07 to $4.11 in 2024 in the past 30 days.
HAE’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 16.1%. In the last reported quarter, it posted an earnings surprise of 5.3%.
Estimates for Insulet’s 2023 earnings per share have increased from $1.61 to $1.90 in the past 30 days. The company's shares have plunged 40.9% in the past year compared with the industry’s decline of 7%.
PODD’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 105.1%. In the last reported quarter, it delivered an average earnings surprise of 77.4%.
Estimates for DexCom’s 2023 earnings per share have increased from $1.23 to $1.41 in the past 30 days. Shares of the company have fallen 7.8% in the past year compared with the industry’s decline of 7.1%.
DXCM’s earnings surpassed estimates in all the trailing four quarters, the average surprise being 36.4%. In the last reported quarter, it delivered an average earnings surprise of 47.1%.